Funding sources The Raynaud's and Scleroderma Association funded a pilot project for this study.
Scanning laser Doppler imaging may predict disease progression of localized scleroderma in children and young adults
Article first published online: 8 JUL 2013
© 2013 The Authors BJD © 2013 British Association of Dermatologists
British Journal of Dermatology
Volume 169, Issue 1, pages 152–155, July 2013
How to Cite
Shaw, L.J., Shipley, J., Newell, E.L., Harris, N., Clinch, J.G. and Lovell, C.R. (2013), Scanning laser Doppler imaging may predict disease progression of localized scleroderma in children and young adults. British Journal of Dermatology, 169: 152–155. doi: 10.1111/bjd.12255
Conflicts of interest None declared.
- Issue published online: 8 JUL 2013
- Article first published online: 8 JUL 2013
- Accepted manuscript online: 3 FEB 2013 09:30PM EST
- Manuscript Accepted: 22 JAN 2013
Localized scleroderma is a rare but potentially disfiguring and disabling condition. Systemic treatment should be started early in those with active disease in key functional and cosmetic sites, but disease activity is difficult to determine clinically. Superficial blood flow has been shown to correlate with disease activity in localized scleroderma.
To examine whether superficial blood flow measured by laser Doppler imaging (LDI) has the potential to predict disease progression and therefore select patients for early systemic treatment.
A group of 20 individuals had clinical assessment and scanning LDI blood-flow measurements of 32 affected body sites. After a mean follow-up of 8·7 months their clinical outcome was compared with the results of the initial LDI assessment.
Eleven out of 15 patients with an assessment of active LDI had progressed clinically, and 16 out of the 17 scans with inactive LDI assessment had not progressed, giving a positive predictive value of 73% and a negative predictive value of 94%.
We believe that LDI can be a useful tool in predicting disease progression in localized scleroderma, and it may help clinicians to decide which patients to treat early.